Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy

  • Price (USD)3.30
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+6.45%
  • Beta--
Data delayed at least 15 minutes, as of Feb 11 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-20.84m
  • Incorporated2006
  • Employees37.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151
  • Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.